All Episodes
The Top Line — 128 episodes
What did we learn from Big Pharma’s Q2 results?
How consumerization is reshaping pharma marketing (Sponsored)
A genomics library for the AI era
The next frontier in patient support: Connected data, AI and personalized engagement (Sponsored)
Novo Nordisk’s CFO on the oral Wegovy rollout and beyond
Inside Noble’s connected approach to patient support (Sponsored)
Psychedelics, peptides and GLP-1s
GSK’s first lung cancer approval, a new IPO path and more
Why modern clinical trials need a finance-first strategy (Sponsored)
5 emerging biotech hubs
Operating at the speed of science: The new medical affairs playbook (Sponsored)
Decision readiness is the next AI advantage (Sponsored)
A $10B deal, China trial scrutiny and highlights from ADA 2026
The deal before the deal
FDA Breakthrough Therapy and RMAT: Strategic Decisions That Can Accelerate Oncology Development (Sponsored)
Ipsen R&D chief on pipeline discipline, partnerships and 2026 milestones
Why MRD is becoming central to oncology drug development (Sponsored)
Behind the headlines of ASCO 2026
Mesutoclax points to possible shift in high-risk MDS and AML (Sponsored)
Boston, China and the future of biotech
Why direct-to-patient is the future of pharma access (Sponsored)
BioAge CEO talks NLRP3 and ‘pipeline in a pill’ ambitions
Designing an agentic, future‑ready tech roadmap for emerging pharma (Sponsored)
Health execs persevere in new policy landscape
Revisiting Pharma’s tariff reality
Setting a new standard in prefillable syringe systems (Sponsored)
Scaling theranostics through access, safety and trust (Sponsored)
A pivotal time for an RNA pioneer
Accelerating clinical trials with precision logistics (Sponsored)
Can Trump’s deal with the UK become a model for similar drug price agreements?
Biomarkers are reshaping oncology trial design (Sponsored)
Fixing failed spray-dried formulations faster (Sponsored)
AI brings precision to pharma content decisions (Sponsored)
Roivant’s CEO thinks China is a ‘red herring’
The top 10 pharma R&D budgets of 2025
An update on the pharma industry’s reshoring effort
Pulse check on Lilly's GLP-1 fortunes
Avoiding 11th hour surprises in clinical trials (Sponsored)
What Xaira is building after its $1B fundraise
Patent expirations push biopharma industry toward a tougher 2026
As AI evolves, the modern R&D lab is changing
How physiology powers biotech innovation (Sponsored)
Autoimmune CAR-T: Navigating the FDA’s new regulatory playbook
Inside the sterile fill capacity crunch (Sponsored)
Trump's tariff threats, measured by manufacturing
Why patient access must keep pace with drug innovation (Sponsored)
What were the biggest clinical trial flops of 2025?
Community oncology’s growing role in the future of cancer care (Sponsored)
The biggest potential drug launches of 2026
How Mirum is Advancing Rare Disease Care Through Strategic M&A (Sponsored)
Why human expertise still matters in AI-driven med comms (Sponsored)
Biopharma's rebound keeping pace so far
JPM26: Sunshine, AI and the deals that weren't
From approval to value: Why evidence storytelling now matters (Sponsored)
Drug approvals went from crawl to sprint in 2025
Putting patients first: from buzzword to business imperative (Sponsored)
Beyond the AI hype: How life sciences can turn agents into a competitive advantage (Sponsored)
China’s biotech moment goes global, Zai Lab exec says (Sponsored)
Biopharma CEOs assess the road ahead in 2026
A year in review and what 2026 holds for biopharma and healthcare
From data to decisions: how Walgreens is powering smarter pharma strategies (Sponsored)
The biopharma dealmaking landscape and what to expect in 2026
Advocacy, access and the future of cancer care take center stage in new Health Matters episode (Sponsored)
2025’s Fiercest Women in Life Sciences are changing the game
Bayer’s collaborative model: Breaking silos to accelerate impact (Sponsored)
Inside Foresight’s mission to redefine cancer monitoring (Sponsored)
Biopharma industry gathers momentum in Q3
PreCheck pulse check: What the industry is saying about FDA’s production initiative
How Pharma Can Build Trust and Reach Patients in Health Marketplaces (Sponsored)
Biotech Graveyard
Fierce 15: Where are they now?
Salesforce’s Mark Sullivan: AI and agentic systems will redefine life sciences (Sponsored)
Unpacking the FDA transparency push on CRLs
How Boehringer Ingelheim is buttressing its US business
AI is changing drug safety, but governance sets the guardrails (Sponsored)
A whirlwind week for pharma
Fierce Biotech's Fierce 15
Rebuilding trust in pharma in the age of misinformation
Schrödinger taps AI to speed drug discovery (Sponsored)
Inside the commercial growing pains of hemophilia gene therapies
A rare kind of leadership, 30 years in the making
Former FDA Chief Scott Gottlieb talks drug pricing, access and innovation (Sponsored)
Big Pharma bounces back in Q2
The battle of the obesity drug heavyweights
Is Trump’s MFN pricing order more bark than bite?
Rebuilding trust: compassionate communication and public health (Sponsored)
Untangling Sarepta’s gene therapy fallout and a growing trust deficit
Making sense of China’s R&D ascent
AI, mentorship and finding your voice in pharma marketing
Biopharma layoffs aren't letting up
Peter Pitts talks FDA direction, industry communication (Sponsored)
Teva’s CEO shares ‘Pivot to Growth’ progress
AbbVie, ADCs and the future of cancer care
Inside Fierce Medtech's Fierce 15
Inside ASCO 2025: Big data drops and a towering campaign
Forging the future of cell therapy: Bayer and BlueRock’s unique journey (Sponsored)
Science-led storytelling takes center stage in pharma communications (Sponsored)
Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview
A Fierce breakdown of the 'most favored nation' executive order
Angela Hwang on her pivot from Big Pharma to biotech
ElevAAte and the push for East Asian American leaders in biopharma
Angus on Angus: A Fierce oncology discussion
Navigating Trump’s tariffs for pharma
Q1 biopharma layoff trends, plus expectations for Q2
A closer look at pharma's top R&D budgets
What diversity means in medtech
5 Key Questions About Precision Patient Marketing—Answered (Sponsored)
A closer look at pharma’s top patent losses in 2025
Agenus CMO touts immunotherapy advances on The Top Line
Breaking down pharma’s fourth-quarter sales boom
Inside the Future of Aseptic Manufacturing with GRAM (Sponsored)
Bridging the gap from clinical trials to real-life HIV care (Sponsored)
A look at biotech's biggest money raisers of 2024
Research reveals ‘ticking DNA clock’ behind Huntington’s disease
What were the biggest clinical trial flops of 2024?
A heartwarming roundup of cardiovascular news and most-loved stories
Looking ahead at the most anticipated drug launches of 2025
What to expect from the biotech IPO market in 2025
Recapping the 2025 J.P. Morgan Healthcare Conference
Fierce's forecasts for the next year in biopharma
An additional treatment option with TAGRISSO® (osimertinib) (Sponsored)
Breaking down the 55 new drug approvals of 2024
Fierce 50 honorees look ahead: AI, rural health, antibiotic resistance, maternal care and more
Novo Nordisk’s chief scientific officer looks to the future of GLP-1s
What can we learn from 2024’s biotech IPOs?
Meet 2024’s fiercest women in life sciences
Misconduct and the future of neurodegenerative disease research
Dig into this year’s Fierce Biotech Graveyard, layoff numbers